BioNTech mRNA cancer immunotherapy misses first objective in key study

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 13 Oct, 16:24 UTC

An early data check showed the shot didn’t delay tumor progression in a form of head and neck cancer, though BioNTech is holding out hope it might eventually extend survival.

science

Sources

• T2BioNTech mRNA cancer immunotherapy misses first objective in key studyBioPharma Dive / Healthcare Dive / MedTech Dive13 Oct, 16:24